Repurposed drug improves outcomes for patients with severe COVID-19 pneumonia

Prespecified Primary and Secondary endpoints. Credit: eLife (2023). DOI: 10.7554/eLife.87030.1 A drug commonly used to treat cystic fibrosis improved outcomes for patients with severe COVID-19 pneumonia and could be used to treat other respiratory infections, according to clinical trial results from researchers at UCL, UCLH and the Francis Crick Institute. The study, published in eLife, found that the drug dornase alfa reduced hyper-inflammation in COVID-19 pneumonia patients, which occurs when the body’s immune system reacts too strongly and can lead to tissue damage and death. The next step will be to conduct larger clinical trials, with the ultimate goal of Read More